Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Allergy Therapeutics (AGY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
33.50 +0.50    +1.51%
22/10 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 512,012
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 33.90 - 33.90
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B02LCQ05 
SEDOL:  B02LCQ0
Allergy Therapeutics 33.50 +0.50 +1.51%
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

ORD

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Contact Information

Top Executives

Name Age Since Title
Manuel Llobet 57 2009 CEO & Executive Director
Peter Sinclair Jensen 70 2010 Independent Chairman
Mary Geraldine Tavener 59 2019 Independent Non-Executive Director
Nicolas Alexander Ulrich Wykeman 56 2016 CFO & Executive Director
Lawrence M. Du Buske - - Member of Scientific Advisory Board
Hendrik Kees Kam Nolte - - Chairman of Scientific Advisory Board
Johannes Ring - - Member of Scientific Advisory Board
Stephen Rushworth Smith 67 2004 Senior Independent Director
Scott Michael Leinenweber 49 2018 Non-Executive Director
Babatunde Adekunle Otulana 64 2017 Independent Non-Executive Director
Anthony James Frew - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AGY Comments

Write your thoughts about Allergy Therapeutics
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Gary Smith
Gary Smith Sep 09, 2020 0:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Am buying tomorrow .( .there might be some good news coming )
Gary Smith
Gary Smith Sep 08, 2020 21:45
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Am buying tomorrow .( ..near might be some good news coming )
Gary Smith
Gary Smith Sep 04, 2020 16:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it a good time to sell
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email